MedTrace Logo

A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)

NCT00092391 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1997

Last updated 2015-10-23

No results posted yet for this study

Summary

The purpose of this study is to determine the mumps virus strength at the end of shelf-life (expiration date) of an approved vaccine.

Conditions

Interventions

BIOLOGICAL

Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live

0.5 mL subcutaneous injection of one of three sub-lots on Day 0

BIOLOGICAL

Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)

0.5 mL subcutaneous injection on Day 0

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Months
Max Age
18 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1999-02-28
Primary Completion
2001-07-31
Completion
2001-07-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00092391 on ClinicalTrials.gov